Tuberc Respir Dis.  2001 Nov;51(5):474-481. 10.4046/trd.2001.51.5.474.

A Case of Mesalazine-induced Eosinophilic Pneumonia in a Patient with Ulcerative Colitis

Abstract

Measlazine(5-Aminosalicylic acid, 5-ASA), a component of Sulfasalazine (sulfapyridine bound to 5-ASA), is used to treat inflammatory bowel disease. Most adverse pulmonary effects caused by sulfasalazine have been attributed to sulfapyridine. However, lung toxicity associated with measlazine(5-ASA) is rare. Here we report a case of eosinophilic pneumonia in a 44-year-old woman with ulcerative colitis, who was treated with mesalazine. She developed symptoms of a dry cough, mild night fever, and evertional dyspnea. Bilateral peripheral pulmonary infiltrates, peripheral blood eosinophilia, and histologic features were consistent with eosinophilic pneumonia. The symptoms improved quite rapidly after the discontinuation of mesalazine and initiation of steroid therapy. Therefore, adverse pulmonary reactions to mesalazine must be considered in a differential diagnosis of pulmonary involvement in patients with inflammatory bowel disease who are receiving with measlazine therapy.

Keyword

Mesalazine; Eosinophilic pneumonia; Ulcerative colitis

MeSH Terms

Adult
Colitis, Ulcerative*
Cough
Diagnosis, Differential
Dyspnea
Eosinophilia
Eosinophils*
Female
Fever
Humans
Inflammatory Bowel Diseases
Lung
Mesalamine
Pulmonary Eosinophilia*
Sulfapyridine
Sulfasalazine
Ulcer*
Mesalamine
Sulfapyridine
Sulfasalazine

Cited by  1 articles

Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis
Myoungrin Park, Junguee Lee, Sang-Bum Kang, Yeonhee Park
Korean J Gastroenterol. 2019;73(4):225-229.    doi: 10.4166/kjg.2019.73.4.225.

Full Text Links
  • TRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr